Objectives: Chordoma is a rare bone malignancy that affects the spine and skull base. Treatment dilemma leads to a high rate of local relapse and distant metastases. Molecular targeted therapy (MTT) ...

Introduction: Cancer stem cells (CSCs), a group of tumor-initiating and tumor-maintaining cells, may be major players in the treatment resistance and recurrence distinctive of chordoma. Characterizing ...

The original data read in R code is not provided in this repository and needs to be extracted in the SEER database according to inclusion criteria (AYA site recode 2020 Revision = 4.13 Chordoma) ...

NUC-7738 is under clinical development by NuCana and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs for Chordoma does not have sufficient historical data to build an ...

Randomised trial of proton vs carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study ...

ESMO also hosted a parallel consensus meeting on chordoma that included more than 40 chordoma experts from several disciplines and from both sides of the Atlantic, with the contribution and ...

Hoping to enlist in the fight against my cancer, I joined the lab of Michael Kelley, an oncologist at Duke, who happened to be the only federally funded chordoma researcher. Meanwhile, my mother ...

Chordoma research is led by a comprehensive team including Gary Gallia, M.D., director of the Neurosurgery Skull Base Tumor Center. The laboratory focuses on developing new therapies for brain and ...

Rachel Sarabia Estrada, D.V.M., Ph.D., in collaboration with Dr. Quinones-Hinojosa's lab, developed and characterized the first orthotopic animal model of human chordoma in an immunocompromised rat.

Mac Sinise died Jan. 5 after a five-year battle with chordoma, a rare type of cancer found in the spine. In his final years, he was dedicated to working with his father's foundation and making music.